Two of three men charged with violating their community control sanctions will be sentenced next month. In one case Tuesday, Matthew L. Carter, 25, of Wakeman, agreed not to fight the allegations of violating his probation.[...]
Mental health research from Southern India
Today some fascinating research from Southern India which can teach Western countries something about ways to treat people with serious mental illness[...]
Natural Good Sleep: Tips on Melatonin, Valerian, and More
What's your ploy for getting a decent night's sleep? A healthy lifestyle is key. Supplements may also help provide restful sleep.[...]
Deaths linked to common anxiety drug soar
USERS of a commonly prescribed drug to treat anxiety and depression have been warned of its addictive and potentially fatal effects after a report revealed soaring misuse rates and identified it as a factor in 31% of all drug-related deaths.[...]
Sedative abuse deaths on rise
THE NUMBER of people seeking treatment for, and dying as a result of, sedative abuse has increased significantly in the past decade, a new report shows.[...]
Check on benzodiazepine-use must be done, say MPs
The safety of tranquillising drugs prescribed to millions of people over the past 50 years must be urgently investigated, MPs and peers will demand this week.[...]
Lundbeck reports positive phase III study results for clobazam in the adjunctive treatment of seizures associated with ...
* Data from the pivotal clobazam study were presented at the American Epilepsy Society meeting in San Antonio, TX * Two highest dosages of clobazam as add-on therapy achieved the primary endpoint with a statistically significant reduction in …[...]
Eisai Submits Marketing Authorization Application In Japan For Insomnia Treatment Sep-190
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced that it has submitted a Marketing Authorization Application (MAA) to the Japanese Ministry of Health, Labour and Welfare seeking approval for SEP-190 (generic name: eszopiclone), a product the company has been developing in Japan, as a treatment for insomnia. SEP-190 is a non-benzodiazepine type GABAA agonist (non.[...]
No comments:
Post a Comment